Team of professionals you given the Benazepril Lotensin blood pressure in ¬ for information about a third of patients with hypertension, another third term is ben two drugs, Ben and the rest Term at least three agents.68 These requirements are reflected in the guidelines Europ He that the use of a combination of two antihypertensive drugs in patients with severe hyper recommend ¬ tension.69 antihypertensive therapy trials in patients with heart failure have shown that mortality can be reduced gradually by the inclusion of new antihypertensive drugs in the regimen was mor tality ¬ allm hlich reduced over the following tests: SOLVD, CIBIS II and rattles, and combination therapy CHARM.70 glicht makes a better reduction in blood pressure, because each agent is usually the activity of T regulatory system to be blocked by reduce other71 loan st and can also impact. For example, the combination of a calcium channel blocker with an AT1R antagonist induces effective in reducing blood pressure than either drug alone, 72 and AT1R blockade dilatation c T curves Sen capillaries reduces the incidence of peripheral-edema caused by calcium channel blockers were reported in patients treated with combination therapy in patients treated with amlodipine compared ¬ mono therapy.72 Similarly, a meta-analysis of 43 randomized, controlled place showed that the addition of the diuretic hydrochlorothiazide AT1R antagonists Born entered a lowering of blood pressure in hypertensive patients showed an improvement, 73 In addition, AT1R blockade induced potassium cesium retention ¬ k nnte for losses to be compensated by increasing potassium diuretic administration.74 interest in the development of combination therapy for cakes ¬their superior efficiency and the potential to allow the blood pressure is difficult to achieve. In addition k Can be patient as little as pills Want to use is possible, 26 fixed-dose combinations and adherence of two agents as a single pill may hold better than in free combinations thereof agents.75 Since 2000, 13 new fixed-dose combination combinations, including three triple therapies approved for the treatment of high blood pressure. Three of these agents, one double and two triple-therapy were approved in 2010 2011th The renin inhibitor aliskiren, was approved to treat mono ¬ in 2007. Three combination therapy with these agents are now available: thiazide ¬ aliskiren plus hydrochlorothiazide, amlodipine plus aliskiren and amlodipine plus aliskiren and hydrochlorothiazide. The combination of aliskiren and amlodipine achieved st Rkere blood pressure reductions than either component alone in patients with severe hypertension after 8 weeks of treatment.76 The approval of aliskiren therapy in a triple fixed-dose combination with amlodipine and hydrochlorothiazide on the results of a double-blind, controlled EAA active treatment in patients with moderate to severe hypertension is based. These data showed that the triple combination achieved an average reduction in blood pressure of more than two combinations of three drugs: aliskiren plus hydrochlorothiazide or amlodipine plus hydrochlorothiazide and aliskiren plus ¬ Zide amlodipine.77 Although no combination of these contain AT1R antagonist or ACE inhibitor such as a combination.